PMID- 17092617
OWN - NLM
STAT- MEDLINE
DCOM- 20070314
LR  - 20131121
IS  - 0264-410X (Print)
IS  - 0264-410X (Linking)
VI  - 25
IP  - 7
DP  - 2007 Jan 26
TI  - Vitamin D3-mediated alterations to myeloid dendritic cell trafficking in vivo 
      expand the scope of their antigen presenting properties.
PG  - 1236-49
AB  - The mucosal immune system provides the host with a first line of adaptive immune 
      defense against invasion by many species of pathogenic microorganisms and their 
      secreted products. Calcitriol, the active form of Vitamin D3 (VD3), promotes the 
      induction of mucosal immunity in mice when added to subcutaneously administered 
      vaccine formulations. Dendritic cells (DCs) activated at vaccination sites where 
      VD3 is present gain the capacity to bypass sequestration in the draining lymph 
      node and traffic to the Peyer's Patches (PP) of immunized animals. By employing 
      protocols that allow the effective tracking of endogenous or adoptively 
      transferred myeloid DCs in vivo, we found that VD3 influences on the trafficking 
      of fully differentiated immature DCs were temporary, and occur without negative 
      effects to antigen processing or peptide presentation to CD4+ T cells. In 
      contrast, DCs differentiated from hematopoietic precursors in the presence of VD3 
      (conditioned DCs), were markedly compromised in their antigen presenting 
      properties, while manifesting clear alterations to their trafficking properties 
      in vivo. Similar to the recent finding of VD3-mediated enhancement of innate 
      immune protection, our findings suggest that VD3 could also play an important 
      role in controlling the types of immune effector responses elicited subsequent to 
      either infection or vaccination.
FAU - Enioutina, Elena Y
AU  - Enioutina EY
AD  - Department of Pathology, University of Utah Medical School, 30 North 1900 East, 
      Salt Lake City, UT 84132, USA. elena.enioutina@path.utah.edu
FAU - Bareyan, Diana
AU  - Bareyan D
FAU - Daynes, Raymond A
AU  - Daynes RA
LA  - eng
GR  - AI059242/AI/NIAID NIH HHS/United States
GR  - DK55491/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20061024
PL  - Netherlands
TA  - Vaccine
JT  - Vaccine
JID - 8406899
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Ccr7 protein, mouse)
RN  - 0 (Receptors, CCR7)
RN  - 0 (Receptors, Chemokine)
RN  - 1C6V77QF41 (Cholecalciferol)
SB  - IM
MH  - *Adjuvants, Immunologic
MH  - Animals
MH  - Antigen Presentation/*drug effects/*immunology
MH  - Bone Marrow Cells/immunology
MH  - CD4-Positive T-Lymphocytes/immunology
MH  - Chemotaxis, Leukocyte/immunology
MH  - Cholecalciferol/*pharmacology
MH  - Dendritic Cells/drug effects/*immunology
MH  - Female
MH  - Immunity, Mucosal/immunology
MH  - Immunotherapy, Adoptive
MH  - Lymphoid Tissue/immunology
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Inbred C3H
MH  - Mice, Transgenic
MH  - Myeloid Cells/drug effects/*immunology
MH  - Receptors, CCR7
MH  - Receptors, Chemokine/biosynthesis/genetics
MH  - Skin/cytology/immunology
EDAT- 2006/11/10 09:00
MHDA- 2007/03/16 09:00
CRDT- 2006/11/10 09:00
PHST- 2006/07/18 00:00 [received]
PHST- 2006/09/22 00:00 [revised]
PHST- 2006/10/05 00:00 [accepted]
PHST- 2006/11/10 09:00 [pubmed]
PHST- 2007/03/16 09:00 [medline]
PHST- 2006/11/10 09:00 [entrez]
AID - S0264-410X(06)01113-3 [pii]
AID - 10.1016/j.vaccine.2006.10.008 [doi]
PST - ppublish
SO  - Vaccine. 2007 Jan 26;25(7):1236-49. doi: 10.1016/j.vaccine.2006.10.008. Epub 2006 
      Oct 24.